drugset
drugset / Trial / NCT06468826

A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)

NCT06468826 ↗

Phase 1 Completed 13 enrolled Amgen
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The primary objective of the study is to evaluate the pharmacokinetics (PK) of avacopan and metabolite (M1) after a single dose of avacopan in participants with normal renal function and participants with ESRD requiring hemodialysis (HD).

Timeline

Start
2024-06-18
Primary completion
2024-10-05
Completion
2024-10-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Avacopan Small molecule — Oral

Indications

end stage renal failure